YB1 TOX
Alternative Names: YB1-TOXLatest Information Update: 12 Jul 2022
Price :
$50 *
At a glance
- Originator University of Hong Kong
- Developer HKND YB1 PHARMACEUTUCAL; University of Hong Kong
- Class Antineoplastics; Bacteria; Proteins
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Malignant melanoma; Sarcoma
Most Recent Events
- 08 Jul 2022 Preclinical trials in Malignant melanoma in China (IV) before July 2022 (HKND YB1 PHARMACEUTUCAL website, July 2022)
- 08 Jul 2022 Preclinical trials in Sarcoma in China (IV) before July 2022 (HKND YB1 PHARMACEUTUCAL website, July 2022)
- 08 Jul 2022 HKND YB1 PHARMACEUTICAL plans a phase I trial in Sarcoma and Melanoma (HKND YB1 PHARMACEUTICAL pipeline, July 2022).